semaglutide heart failure fda Approves for New Indication Involving Cardiovascular Disease Semaglutide in Patients with Heart

P.IselyC.StruckmanH

Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with CVD and either obesity or overweight, John Sharretts, MD, director of the division of diabetes, lipid disorders and obesity in the FDAs Center for Drug Evaluation and Research, said in the statement

Weight loss, appetite changes, and blood sugar improvements are much more reliable indicators

We use carefully calibrated low doses as part of a holistic strategy that may support metabolic health while simultaneously addressing nutrition quality, movement patterns, hormonal balance, sleep optimization, stress management, and mindset

They may suggest taking your dose as soon as you remember, and then making that the new injection day for your medication moving forward